Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.
Auteurs : Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, Romano E, Rothé F, Sotiriou C, Buisseret L Année : 2023 Journal : J Clin Med
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.
Auteurs : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG Année : 2022 Journal : Cancer Discov
Incorporation of TILs in daily breast cancer care: how much evidence can we bear?
Auteurs : Lænkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R Année : 2022 Journal : Virchows Arch
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.
Auteurs : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S Année : 2022 Journal : NPJ Breast Cancer
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G Année : 2022 Journal : NPJ Breast Cancer